FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McDade Ralph L
2. Issuer Name and Ticker or Trading Symbol

MYRIAD GENETICS INC [ MYGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President Myriad RBM, Inc.
(Last)          (First)          (Middle)

320 WAKARA WAY
3. Date of Earliest Transaction (MM/DD/YYYY)

9/30/2019
(Street)

SALT LAKE CITY, UT 84108
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/30/2019    D(1)    2361  D $28.63  145047  D   
Common Stock  9/30/2019    D(1)    2952  D $28.63  142095  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
McDade Ralph L
320 WAKARA WAY
SALT LAKE CITY, UT 84108


President Myriad RBM, Inc.

Signatures
By: Benjamin Jackson For: Ralph McDade 10/1/2019
**Signature of Reporting Person Date


Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Myriad Genetics Charts.
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Myriad Genetics Charts.

Myriad Genetics Inc News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
Friday 17 May 2024 (7 days ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 16 May 2024 (1 week ago) • Edgar (US Regulatory)
Form 4 - Statement of changes in beneficial ownership of securities
Thursday 16 May 2024 (1 week ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Thursday 16 May 2024 (1 week ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Wednesday 15 May 2024 (1 week ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Tuesday 14 May 2024 (1 week ago) • Edgar (US Regulatory)
Form 144 - Report of proposed sale of securities
Tuesday 14 May 2024 (1 week ago) • Edgar (US Regulatory)
Reddit Rises 15% After First Quarterly Report, Upstart and Twilio Plunge Due to Weak Q2 Forecast, and More in Earnings
Wednesday 8 May 2024 (2 weeks ago) • IH Market News
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 8 May 2024 (2 weeks ago) • Edgar (US Regulatory)
Form 8-K - Current report
Wednesday 8 May 2024 (2 weeks ago) • Edgar (US Regulatory)
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
Wednesday 8 May 2024 (2 weeks ago) • GlobeNewswire Inc.
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
Tuesday 7 May 2024 (2 weeks ago) • GlobeNewswire Inc.